정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2340 | Completed | A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities for COVID-19 | Severe Acute Respiratory Syndrome | Biological: CVnCoV Vaccine | Phase 3 | CureVac AG | INDUSTRY | 129 | All | 18 Years | Centre Hospitalier Universitaire Saint-Pierre, Brussels, Belgium Universite Libre de Bruxelles (ULB) - Hopital Erasme, Brussels, Belgium Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc, Brussels, Belgium Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman, Liege, Belgium |
| 2339 | Active, not recruiting | A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 | SARS-CoV-2 | Biological: mRNA-1283 Biological: mRNA-1273 Biological: Placebo |
Phase 1 | ModernaTX, Inc. | INDUSTRY | 106 | All | 18 Years ~ 55 Years | Synexus Clinical Research US Phoenix Southeast, Inc., Chandler, Arizona, United States Optimal Research San Diego, LLC, San Diego, California, United States Optimal Research Melbourne, LLC, Melbourne, Florida, United States Optimal Research Illinois, LLC, Peoria, Illinois, United States Optimal Research Texas, LLC, Austin, Texas, United States |
| 2338 | Active, not recruiting | A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults | COVID-19 | Biological: BNT162b2 | Phase 3 | BioNTech SE, Pfizer | INDUSTRY | 629 | All | 18 Years ~ 55 Years | Anaheim Clinical Trials, LLC, Anaheim, California, United States Diablo Clinical Research, Inc., Walnut Creek, California, United States Indago Research & Health Center, Inc, Hialeah, Florida, United States Research Centers of America ( Hollywood ), Hollywood, Florida, United States Clinical Neuroscience Solutions, Inc. dba CNS Healthcare, Jacksonville, Florida, United States Clinical Neuroscience Solutions, Orlando, Florida, United States Clinical Research Atlanta, Stockbridge, Georgia, United States East-West Medical Research Institute, Honolulu, Hawaii, United States Solaris Clinical Research, Meridian, Idaho, United States Kentucky Pediatric/ Adult Research, Bardstown, Kentucky, United States Meridian Clinical Research, LLC, Omaha, Nebraska, United States Amici Clinical Research LLC, Raritan, New Jersey, United States Accellacare (formerly PMG Research of Wilmington, LLC), Wilmington, North Carolina, United States Aventiv Research Inc, Columbus, Ohio, United States Benchmark Research, Austin, Texas, United States University of Texas Medical Branch, Galveston, Texas, United States Texas Center for Drug Development, Inc., Houston, Texas, United States DM Clinical Research (Administrative and Storage Office only), Tomball, Texas, United States Martin Diagnostic Clinic, Tomball, Texas, United States J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City, Utah, United States J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City, Utah, United States |
| 2337 | Recruiting | A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19 | Coronavirus | Biological: Baiya SARS-CoV-2 Vax 1 | Phase 1 | Baiya Phytopharm Co., Ltd., National Vaccine Institute, Thailand | INDUSTRY | 96 | All | 18 Years ~ 75 Years | Chula Clinical Research Center (Chula CRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Queen Saovabha Memorial Institute, Bangkok, Thailand |
| 2336 | Recruiting | A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study) | COVID-19 | Drug: RBT-9 (90 mg) Drug: 0.9% sodium chloride (normal saline) |
Phase 2 | Renibus Therapeutics, Inc. | INDUSTRY | 252 | All | 18 Years | New Smyrna Beach, FL, New Smyrna Beach, Florida, United States Berkley, MI, Berkley, Michigan, United States El Paso, TX, El Paso, Texas, United States Fort Worth, TX, Fort Worth, Texas, United States Houston, Houston, Texas, United States |
| 2335 | Recruiting | A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19 | Covid19 | Drug: Niclosamide suspension Other: Placebo |
Phase 3 | Imuneks Farma ilac San. Tic. A.S. | INDUSTRY | 200 | All | 18 Years | Akdeniz Universitesi Tıp Fakultesi Hastanesi, Antalya, Turkey Antalya E?itim ve Ara?tırma Hastanesi, Antalya, Turkey Gaziantep Universitesi Tıp Fakultesi Hastanesi, Gaziantep, Turkey Gaziosmanpa?a Taksim E?itim ve Ara?tırma Hastanesi, Istanbul, Turkey Dokuz Eylul Universitesi Hastanesi, ?zmir, Turkey ?zmir SBU Tepecik E?itim ve Ara?tırma Hastanesi, ?zmir, Turkey SBU Dr. Suat Seren Go?us Hastalıkları ve Cerrahisi E?itim ve Ara?tırma Hastanesi, ?zmir, Turkey ?zmir Katip Celebi Universitesi Ataturk E?itim ve Ara?tırma Hastanesi, ?zmir, Turkey |
| 2334 | Completed | A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19 | COVID-19 | Drug: Brilacidin Drug: Placebo Drug: Standard of Care (SoC) |
Phase 2 | Innovation Pharmaceuticals, Inc. | INDUSTRY | 120 | All | 18 Years ~ 80 Years | IPI Investigator Site, Winfield, Illinois, United States IPI Investigator Site, Toledo, Ohio, United States IPI Investigator Site, Barnaul, Russian Federation IPI Investigator Site, Moscow, Russian Federation IPI Investigator Site, Moscow, Russian Federation IPI Investigator Site, Moscow, Russian Federation IPI Investigator Site, Moscow, Russian Federation IPI Investigator Site, Nizniy Novgorod, Russian Federation IPI Investigator Site, Pushkin, Russian Federation IPI Investigator Site, Saint Petersburg, Russian Federation IPI Investigator Site, Saint Petersburg, Russian Federation IPI Investigator Site, Saint Petersburg, Russian Federation |
